Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bavituximab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Giving paclitaxel together with bavituximab
may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects of giving paclitaxel and bavituximab
together in treating patients with Human Epidermal growth factor Receptor 2 (HER2 )-negative
metastatic breast cancer